Address: ul. Domaniewska 49, 02-672 Warszawa
Tel: +48 22 345 93 00
Web: http://www.teva.pl/u235/navi/73
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals as well as active pharmaceutical ingredients. Teva is among the top 15 pharmaceutical companies and among the largest generic pharmaceutical companies in the world.
In Poland we operate together with a Teva group members – Teva Kutno and PLIVA Kraków – a Polish medicines producers with many years of history and experience.
For over 70 years now we have been with Polish doctors, pharmacists and patients. Today, we are a state-of-the-art and dynamically developing pharmaceutical company, offering prescription medicines and OTC products (sold without prescription, over the counter).
We produce and market medicines used in infections, type 2 diabetes, urological diseases, osteoporosis, central nervous system disorders, heart and respiratory diseases, for transplantations and cancer treatment.
Teva’s manufacturing sites in Kutno and Kraków meets highest standards in manufacturing and controlling pharmaceutical products.
Owing to membership in Teva global concern, access to state-of-the-art technologies and research and development works we will keep expanding our offer for doctors and pharmacists with top quality medicines at prices affordable for patients.
Teva’s scope of activity extends to many facets of the industry, with a primary focus on the manufacturing and marketing of products in the following categories:
Human pharmaceuticals
Teva produces generic drugs in all major therapeutics and steriles in a variety of dosage forms, from tablets and capsules to ointments, creams and liquids.
In addition, Teva manufactures innovative drugs in niche markets where it has a relative advantage in research and development.
Active Pharmaceutical Ingredients (API)
Teva competitively distributes its API to manufacturers worldwide as well as supports its own pharmaceutical production. These activities, which comprise the core businesses of the company, account for 90% of Teva’s total sales.
“We have made some progress in terms of the conceptualization of depression as a disease. Previously, the popular attitude was that depression was a temporary emotion; one that could be…
IMS’ General Manager, Maciej Kuzmierkiewicz, discusses the effects of the Reimbursement Act—the new legislative framework implemented in January 2012—which completely reshaped the rules of the game for the Polish pharmaceutical sector…
You have been heading the affiliate since its creation in 1997; therefore you saw its evolution and growth. Would you say that Apotex Poland has evolved in accordance with the…
You have been heading the affiliate since its creation in 1997; therefore you saw its evolution and growth. Would you say that Apotex Poland has evolved in accordance with the…
You have been quite recently appointed at the head of the Polish affiliate of AstraZeneca. With which personal ambitions did you come and what was the mission you were given…
The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable. The market size is over 5 billion Euros which makes Poland the 6th biggest market…
You were appointed general manager of Astellas Poland in early 2006, only a bit after Astellas Pharma Inc. was established, on April 1, 2005 through the merger of the mother…
BAUSCH + LOMB has over 150 years of heritage and has always been associated with optics and ophthalmology. Therefore the company has been able to build a very strong brand…
Given Cegedim’s global reach and your 13 year experience of operating as a consultant to the Polish pharma industry, how would you describe the market to the international readers of…
As Squibb Corporation and Bristol-Myers merged in 1989, Bristol-Myers Squibb has been officially operating in this market since that date, but the affiliate has a long history previous to that.…
Would you begin by explaining to the readers of Pharmaceutical Executive the importance of the operation in Poland for the company? Indeed Poland because of largest in CEE pharmaceutical market…
Firstly, what attracted you to join the CRO industry with Quintiles over 10 years ago? I had been working for 5 years as a doctor in the internal medicine and…
See our Cookie Privacy Policy Here
